The global non-alcoholic steatohepatitis (NASH) market was valued at US$1.65 billion in 2021. The market value is projected to grow to US$15.04 billion by 2027. Non-Alcoholic Steatohepatitis (NASH) is an inflammatory liver disease associated with excessive fat accumulation in the liver (steatosis), hepatocellular ballooning, and inflammation. Non-Alcoholic Steatohepatitis or “Silent Liver Disease” leads to scarring of the liver, a kind of liver disorder caused by long-term abuse of alcohol but mainly develops in patients who are non-alcoholic or consume very little alcohol. Non-Alcoholic steatohepatitis (NASH) is the second stage of non-alcoholic fatty liver disease (NAFLD) that has progressed to the point of liver inflammation and cell damage.

The factors such as increased investment in medical infrastructure, rising consumption of processed foods containing polyunsaturated fatty acids & fructose, increased focus on development of new drugs and many companies engaged in the launch of non-invasive diagnostic procedures, are expected to drive the overall market growth in the forecasted period. The market is anticipated to grow at a CAGR of approx. 50% during the forecasted period of 2022-2027.

Scope of the Report:

The report titled “Global Non-Alcoholic Steatohepatitis (NASH) Market: Analysis By Drug Type (Vitamin E & Pioglitazone, Ocaliva, Elafibranor, Selonsertib & Cenicriviroc and Others), By Application Type (Treatment and Diagnosis), By Distribution Type (Retail Pharmacies, Hospital Pharmacies and Online Pharmacies), By Region Size and Trends with Impact of COVID-19 and Forecast up to 2027”, includes :

-- An in-depth analysis of non-alcoholic steatohepatitis market by value, by drug type, by application type, by distribution type, by region, etc.

-- The regional analysis of the non-alcoholic steatohepatitis market, including the following regions:

North America (The US, Canada, and Mexico)
Europe (Germany, UK, France, Italy, Spain and Rest of Europe)
Asia Pacific (China, Japan, India, Australia, South Korea and Rest of Asia Pacific)
Middle East & Africa
Latin America

-- Comprehensive information about emerging markets. This report analyses the market for various segments across geographies.

-- Provides an analysis of the COVID-19 impact on the global non-alcoholic steatohepatitis market.

-- Assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall non-alcoholic steatohepatitis market has also been forecasted for the period 2022-2027, taking into consideration the previous growth patterns, the growth drivers, and the current and future trends.

-- Evaluation of the potential role of the non-alcoholic steatohepatitis to improve the market status.

-- Identification of new technological developments, R&D activities, and product launches occuring in the non-alcoholic steatohepatitis market.

-- In-depth profiling of the key players, including the assessment of the business overview, market strategies, regional and business segments of the leading players in the market.

-- The recent developments, mergers and acquisitions related to mentioned key players are provided in the market report.

-- The in-depth analysis provides an insight into the market, underlining the growth rate and opportunities offered in the business.

For further details, kindly visit :

https://www.daedal-research.com/pharma-healthcare/global-non-alcoholic-steatohepatitis-nash-market-size-and-trends-with-impact-of-covid-19-and-forecast-up-to-2027

Rajeev Kumar
(Business Development Manager)
Address: 36 SFS Flats
Paschim Vihar
New Delhi-110063
Mobile: +91-9811715635
Tel: +91-120-4553017
Mail ID - [email protected]